These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 19411636)

  • 21. Source and purity of factor VIII products as risk factors for inhibitor development in patients with hemophilia A.
    Mancuso ME; Mannucci PM; Rocino A; Garagiola I; Tagliaferri A; Santagostino E
    J Thromb Haemost; 2012 May; 10(5):781-90. PubMed ID: 22452823
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Blockade of CD40/CD40 ligand interactions prevents induction of factor VIII inhibitors in hemophilic mice but does not induce lasting immune tolerance.
    Reipert BM; Sasgary M; Ahmad RU; Auer W; Turecek PL; Schwarz HP
    Thromb Haemost; 2001 Dec; 86(6):1345-52. PubMed ID: 11776297
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lack of evidence for increased inhibitor incidence in patients switched from plasma-derived to recombinant factor VIII.
    Scharrer I; Ehrlich HJ
    Haemophilia; 2001 Jul; 7(4):346-8. PubMed ID: 11442637
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Understanding FVIII/VWF complex--report from a symposium of XXIX WFH meeting 2010.
    Gringeri A; Ofosu FA; Grancha S; Oldenburg J; Ewing NP; Federici AB
    Haemophilia; 2012 May; 18(3):469-75. PubMed ID: 21943193
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Superior in vivo response of recombinant factor VIII concentrate in children with hemophilia A.
    Kelly KM; Butler RB; Farace L; Cohen AR; Manno CS
    J Pediatr; 1997 Apr; 130(4):537-40. PubMed ID: 9108849
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical evaluation of recombinant human factor VIII (BAY w 6240) in the treatment of hemophilia A.
    Fukui H; Yoshioka A; Shima M; Tanaka I; Koshihara K; Fukutake K; Fujimaki M
    Int J Hematol; 1991 Oct; 54(5):419-27. PubMed ID: 1756252
    [TBL] [Abstract][Full Text] [Related]  

  • 27. More than a decade of international experience with a pdFVIII/VWF concentrate in immune tolerance.
    Santagostino E
    Haemophilia; 2013 Jan; 19 Suppl 1():8-11. PubMed ID: 23278994
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison among plasma-derived clotting factor VIII by using monodimensional gel electrophoresis and mass spectrometry.
    Timperio AM; Gevi F; Grazzini G; Vaglio S; Zolla L
    Blood Transfus; 2010 Jun; 8 Suppl 3(Suppl 3):s98-104. PubMed ID: 20606759
    [TBL] [Abstract][Full Text] [Related]  

  • 29. von Willebrand factor and transforming growth factor-beta modulate immune response against coagulation factor VIII in FVIII-deficient mice.
    Kallas A; Kuuse S; Maimets T; Pooga M
    Thromb Res; 2007; 120(6):911-9. PubMed ID: 17376515
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The uptake of recombinant Factor VIII in the Netherlands.
    Zwart-van Rijkom JE; Plug I; Rosendaal FR; Leufkens HG; Broekmans AW;
    Br J Haematol; 2002 Nov; 119(2):332-41. PubMed ID: 12406065
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Induction of human factor VIII inhibitors in rats by immunization with human recombinant factor VIII: a small animal model for humans with high responder inhibitor phenotype.
    Jarvis MA; Levin LG; Harrison JA; DePianto DJ; Suzuki CM; Ziaja CL; Brown JE; Jolly KW; Reisner HM; Abildgaard CF; Powell JS
    Thromb Haemost; 1996 Feb; 75(2):318-25. PubMed ID: 8815584
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cumulative inhibitor incidence in previously untreated patients with severe hemophilia A treated with plasma-derived versus recombinant factor VIII concentrates: a critical systematic review.
    Franchini M; Tagliaferri A; Mengoli C; Cruciani M
    Crit Rev Oncol Hematol; 2012 Jan; 81(1):82-93. PubMed ID: 21277222
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparative glycosylation mapping of plasma-derived and recombinant human factor VIII.
    Qu J; Ma C; Xu XQ; Xiao M; Zhang J; Li D; Liu D; Konkle BA; Miao CH; Li L; Xiao W
    PLoS One; 2020; 15(5):e0233576. PubMed ID: 32442215
    [TBL] [Abstract][Full Text] [Related]  

  • 34. OBI-1, porcine recombinant Factor VIII for the potential treatment of patients with congenital hemophilia A and alloantibodies against human Factor VIII.
    Toschi V
    Curr Opin Mol Ther; 2010 Oct; 12(5):617-25. PubMed ID: 20886394
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A shift towards a T cell cytokine deficiency along with an anti-inflammatory/regulatory microenvironment may enable the synthesis of anti-FVIII inhibitors in haemophilia A patients.
    Chaves DG; Velloso-Rodrigues C; Oliveira CA; Teixeira-Carvalho A; Santoro MM; Martins-Filho OA
    Clin Exp Immunol; 2010 Dec; 162(3):425-37. PubMed ID: 20846164
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Anti-CD3 prevents factor VIII inhibitor development in hemophilia A mice by a regulatory CD4+CD25+-dependent mechanism and by shifting cytokine production to favor a Th1 response.
    Waters B; Qadura M; Burnett E; Chegeni R; Labelle A; Thompson P; Hough C; Lillicrap D
    Blood; 2009 Jan; 113(1):193-203. PubMed ID: 18815284
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Recombinant factor VIII Fc (rFVIIIFc) fusion protein reduces immunogenicity and induces tolerance in hemophilia A mice.
    Krishnamoorthy S; Liu T; Drager D; Patarroyo-White S; Chhabra ES; Peters R; Josephson N; Lillicrap D; Blumberg RS; Pierce GF; Jiang H
    Cell Immunol; 2016 Mar; 301():30-9. PubMed ID: 26775174
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Recombinant vs. plasma-derived products, especially those with intact VWF, regarding inhibitor development.
    Ettingshausen CE; Kreuz W
    Haemophilia; 2006 Dec; 12 Suppl 6():102-6. PubMed ID: 17123402
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunoprotective effect of von Willebrand factor towards therapeutic factor VIII in experimental haemophilia A.
    Delignat S; Repessé Y; Navarrete AM; Meslier Y; Gupta N; Christophe OD; Kaveri SV; Lacroix-Desmazes S
    Haemophilia; 2012 Mar; 18(2):248-54. PubMed ID: 22044692
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Enhancement of haemostatic efficacy of plasma-derived FVIII by formulation with PEGylated liposomes.
    Dayan I; Robinson M; Baru M
    Haemophilia; 2009 Sep; 15(5):1006-13. PubMed ID: 19486171
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.